In this review, the authors explore the risk of COVID-19 in PD patients in terms of susceptibility to severe disease, impact on PD disease severity, potential long-term sequelae, and difficulties of PD management during this outbreak.

In this correspondence recently published in Lancet Neurology, the authors report the results of the pilot phase of an investigation of effects of COVID-19 among Italian people with multiple sclerosis, based on a core dataset collected from treatment providers through a specifically designed web-based case report form.

In this paper, the authors report a patient treated with natalizumab for relapsing-remitting MS who developed COVID-19 and recovered in a few days without complications.

In this case report recently published in Neurology, Barzegar et al. present the case of a 42-year-old woman affected by relapsing-remitting MS treated with fingolimod who was diagnosed with COVID-19 and had a favourable outcome.

In this retrospective multicentre cohort study, just published in JAMA, the authors describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19.

In this multicentre, prospective, open-label, randomised, phase 2 trial the authors assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19.

In this observational study recently published in the New England Journal of Medicine, the authors examined the association between hydroxychloroquine use and intubation or death at a large medical centre in New York City.

In this Viewpoint recently published in Lancet Rheumatology, the authors summarised the immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.

The objective of this prospective cohort study was to validate and compare clinical findings with data from medical autopsy, virtual autopsy, and virological tests of 12 patients who died with a polymerase chain reaction– confirmed diagnosis of COVID-19.

The pandemic of COVID-19 continues to affect much of the world. Knowledge of diagnostic tests for SARS-CoV-2 is still evolving, and a clear understanding of the nature of the tests and interpretation of their findings is important.

I believe that the covid-19 pandemic showed us that we, as neurologists, are physicians first, and neurologists second. In other words, as neurology has increasingly developed into an acute care field, it is important that we are not only specialists in neurology, but also strive to build and keep expertise in fields adjacent to our core competences.

Rare neurological diseases are usually hereditary chronic disorders, affecting the central, peripheral nervous system and skeletal muscle, with clinically heterogeneous manifestations.

In this paper published in Neurology, the authors conducted a scoping review of available literature on COVID-19 to assess the potential impact on neurologists in terms of prevalent comorbidities and incidence of new neurological events in patients hospitalized with COVID-19.

n this paper recently published in JAMA, the authors evaluated the prevalence, intensity, and timing of an altered sense of smell or taste in mildly symptomatic patients with SARS-CoV-2 infection.

In this letter, recently published in the European Journal of Neurology, Sellner et al., emphasise that neurologists need to be part of the multidisciplinary team taking care of COVID-19 patients.